Immunohistochemical detection of bcl2, p53, mdm2 and p2l/waf1 proteins in small-cell lung carcinomas

Anticancer Research

Volumn 18, Issue 2 A, 1998, Pages 1167-1173

  Stefanaki, K ^a,b   Rontogiannis, D ^a   Vamvouka, C ^a   Bolioti, S ^b   Chaniotis, V ^b   Sotsiou, F ^c   Vlychou, M ^b   Delidis, G ^b   Kakolyris, S ^b   Georgoulias, V ^b   Kanavaros, P ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c Department of Oncology University Hospital of Heraklion ^*

Author keywords

bcl 2 protein; mdm 2 protein; P2 waf1 protein; Small cell lung carcinomas

Indexed keywords

PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CLINICAL ARTICLE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOMA; LUNG SMALL CELL CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 15644378379     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Hockenbery D: Defining apoptosis. Am JPathol 146: 16-19, 1995.
2. Kerr JFR, Winterford CM, Hermon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 73: 2013-26, 1994.
3. Lu QL, Abel P, Foster C, Lalani EN: Bcl-2 role in epithelial differentiation and oncogenesis. Hum Pathol 27: 102-110, 1993.
4. Reed JD: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
5. Ben-Ezra JM, Kornstein MJ, Grimes MM, Krystal G: Small cell carcinomas of the lung express the bcl-2 protein. Am J Pathol 145: 1036-1040, 1994.
6. Bhargava V. Kell DL, Van de Rijn M, Warnke RA: Bcl-2 immunoreactivity in breast carcinomas correlates with hormone receptor positivity. Am J Pathol 145: 535-540, 1994.
7. Bronner MP, Culin C, Reed JC, Furth EE: The bcl-2 proto-oncogene and the gastrointestinal epithelial tumour progression model. Am J Pathol 146: 20-26, 1995.
8. Jiang SX, Kuwao S, Kameya T, Sato Y, Yanase N, Yoshimura H, Kodama T: Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am J Pathol 148: 837-846, 1996.
9. Levine A, Mormand J, Finlay C: The p53 tumour suppressor gene. Nature 351: 453-456, 1992.
10. Harris CC: P53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262: 1980-1981, 1993.
11. Nigro MJ, Baker SJ, Presinger AC, Jessup JM, HOSTERER r, Cleary K, Binger SH, Davidson N, Baylin S, Devilee P: Mutations in the p53 gene occur in diverse human tumours types. Nature 342: 705-708, 1989.
12. Villuendas R, Piris MA, Algara P, Sanchez-Beato M, Sanchez-Verde L, Martinez JC, Orrade JL, Garcia P. Lopez C, Martinez P: The expression of p53 protein in Non-Hodgkin's lymphomas is not always dependent on p53 mutations. Blood 82: 3151-3156, 1993.
13. Kocialkowski S, Pezzela F, Morrison H, Jones M, Laha S, Harris AL, Mason DY, Gatter KC:Mutations in the p53 gene are not limited to classic "hot spots" and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br J Haematol 89: 55-60, 1995.
14. Barak Y, Oren M: Enhanced binding of a 95 Kd protein to p53 in cells undergoing p53 -mediated growth arrest, EMBO J 11: 2115-2121, 1992.
15. Finlay CA: The mdm-2 oncogene can overcome wild type p53 suppression of transformed cell growth. Moll Cell Biol 13: 301-306, 1993.
16. Mormand J, Zambetti GP, Olson DC, George DL, Levine AJ: The mdm-2 oncogene product forms a complex with p53 protein and inhibits p53 mediated transactivation. Cell 69: 1237-1245, 1992.
17. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein mdm2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860, 1993.
18. Juven T, Barak Y, Zauberman A, George DL, Oren M: Wild type p53 can mediate sequence-specific transactivation of an internai promoter within the mdm2 gene. Oncogene 8: 3411-3416, 1993,
19. Wu X, Bayle H, Olson D, Levine AJ: The p53 mdm2 autoregulation feedback loop. Genes Dev 7: 1126-1132, 1993.
20. Chen CY, Oliner JD, Zhan Q, Fornace AJ, Vogelstein B, Kastan MB: Interactions between p53 and mdm2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci 91: 2684-2688, 1994.
21. El Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzel KW, Vogelstein B: Waf-1 a potential mediator of p53 tumour suppression. Cell 75: 817-825, 1993.
22. Harper JW, Adami GR, Wei N, Keyomashi K, Elledge SJ: The p21 CDK interacting protein Cip 1 is a potent inhibitor of G1 cyclin dependent kinases. Cell 75: 805-816, 1993.
23. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: P21 is universal inhibitor of cyclin kinase. Nature 366: 701 -704, 1993.
24. Wga S, Hannon GJ, Beach D, Stilman B: The p21 inhibitor of cyclindependent kinase controls DNA replications by interactions with PCNA. Nature 369: 574-578, 1994.
25. Barbareschi M, Girlando S, Mauri FA, Arrigoni G, Laurino L, Palma PD, Doglioni C: Tumour suppressor gene products, proliferation and differentiation markers in lung neuroendocrine neoplasms. J Pathol 166: 343-350, 1992.
26. Wang DW, Johnston CF, Anderson N, Sloan JM, Buchanan KD: Overexpression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis. J Pathol 175: 397-401, 1995.
27. Takahashi T, Toshitada T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y, Ueda R: The p53 gene is very frequently mutated in small cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 6: 1775-1778, 1991.
28. Miyashita T, Krajewki S, Krajewska M, Wang HG, Lin HK, Hoffman B, Lieberman D, Reed JC: Tumour suppressor p53 is a regulator of bcl-2 and bax in gene expression in vitro and in vitro. Oncogene 9: 1799-1805, 1994.
29. World Health Organization: The World Health Organization histological typing loop. Genes Dev 7: 1126-1132, 1982.
30. Hsu SM, Raine L, Fanger H: Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques. A comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 29: 557-580, 1981.
31. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdullaziz Z, McDonald S, Pulford KAF, Stein H, Mason D: Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase. (APAAP COMPLEXES). J Histochem Cytochem 32: 219-222, 1984.
32. Kanavaros P, Kouvidou C, Dai Y, Tzardi M, Rontogianni D, Darivianaki K, Delides G: Mdm-2 protein expression in nasopharyngeal carcinomas. Comparative study with p53 expression. J Clin Pathol (Mol. Patbol) 48: M322-M325, 1995.
33. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y: Expression of bcl-2 in small cell lung carcinoma cells Cancer Res 54: 6-8, 1994.
34. Lu QL, Poulsin R, Wong L, Hanby A: Bcl-2 expression in adult and embryonic non-haematopoietic tissues. JPathl 169: 431-437, 1996.
35. Fisher TC, Milner AE, Gregory CD, Jackman AL, Aberne W, Hartley JA, Dive C, Hickman JA: Bcl-2 modulation of apoptosis induced by anticancer drugs: Resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 53: 3321-3326, 1993.
36. Ohmori T, Rodack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, Kubota N, Funayama Y, Ogasawara H, Ohira T, Saijo N: Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bel -2. Biochem Biophys Res Comm 192: 30-36, 1993.
37. Bodner SM, Kell DL, Van de Rijn M, Warnke RA: Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Palhol 145: 535-540, 1994.
38. D'Amico D, Carbone D, Mistudomi T, Nau M, Fedorko J, Russel E, Johnson B, Buchhagen D, Bodner S, Phelps R, Gazdar A, Minna JD: High frequency of somatically acquired mutations in small cell lung lines and tumours. Oncogene 7: 339-346, 1992.
39. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP: Development of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis. J Pathol 175: 397-401, 1992.
40. Oliner JD, Kinzler KW, Meltzer P, George DL, Vogelstein B: Amplification of a gene encoding a p53 associated protein in human sarcoma. Nature 358: 80-83, 1992.
41. Giuseppe Di JA, Redston MS, Yeo JC, Kern SE, Hruban RH: P53-independent expression of the cyclin dependent kinase inhibitor in pancreatic carcinoma. Am J Pathol 747: 884-888, 1995.
42. waf1/CIP1 in differentiating human leukemic cells. J Clin Invest 95: 973-979, 1995.
43. Miyashita T, Harigai M, Hanada M, Reed JC: Identification of a p53 dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131-3135, 1994.
44. Herdar S, Negrini M, Monne, Sabbioni S, Croce CM: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095-2097, 1994.
45. Young RL and Korsmeyer SJ: A negative regulatory element in the bcl-2 5′-untranslated region inhibits expression from an upstream promoter. Mol CeI Biol 13: 3686-3697, 1993.